Your browser is no longer supported. Please, upgrade your browser.
Settings
ELOX Eloxx Pharmaceuticals, Inc. daily Stock Chart
ELOX [NASD]
Eloxx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own0.30% Shs Outstand33.93M Perf Week14.72%
Market Cap412.59M Forward P/E- EPS next Y-1.70 Insider Trans- Shs Float25.06M Perf Month5.74%
Income-47.20M PEG- EPS next Q-0.41 Inst Own52.90% Short Float5.27% Perf Quarter16.36%
Sales- P/S- EPS this Y69.30% Inst Trans-0.02% Short Ratio48.50 Perf Half Y-1.78%
Book/sh1.22 P/B9.97 EPS next Y-3.00% ROA-99.00% Target Price21.40 Perf Year16.36%
Cash/sh1.43 P/C8.49 EPS next 5Y- ROE-112.50% 52W Range9.12 - 24.60 Perf YTD1.25%
Dividend- P/FCF- EPS past 5Y50.80% ROI- 52W High-50.57% Beta1.65
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low33.32% ATR0.91
Employees29 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)55.82 Volatility9.66% 7.36%
OptionableNo Debt/Eq0.00 EPS Q/Q91.60% Profit Margin- Rel Volume1.17 Prev Close11.99
ShortableYes LT Debt/Eq0.00 EarningsMar 08 BMO Payout- Avg Volume27.23K Price12.16
Recom1.80 SMA208.73% SMA501.08% SMA200-11.10% Volume31,806 Change1.42%
Dec-24-18Initiated H.C. Wainwright Neutral $10
Jul-03-18Initiated Citigroup Buy
Apr-22-19 09:37AM  Eloxx Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019 GlobeNewswire
Apr-15-19 01:15PM  Eloxx Pharmaceuticals to Participate in the 2019 5th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit on May 7, 2019 GlobeNewswire
Apr-11-19 02:45PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Eloxx Pharmaceuticals, Inc. ACCESSWIRE
12:07PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Eloxx Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Mar-27-19 09:00AM  Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the European Cystic Fibrosis Society (ECFS) Basic Science Conference GlobeNewswire
Mar-26-19 12:11PM  Proteostasis Plunges on Weak Data From Cystic Fibrosis Study Zacks
Mar-20-19 12:19PM  Eloxx Pharmaceuticals to Present at the Guggenheim Rare Disease & Genomic Medicines Day on April 2, 2019 GlobeNewswire -7.80%
Mar-12-19 11:35PM  Edited Transcript of ELOX earnings conference call or presentation 8-Mar-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-08-19 11:39AM  Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update GlobeNewswire
Mar-05-19 09:08AM  Eloxx Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 GlobeNewswire
Feb-26-19 04:02PM  Eloxx Pharmaceuticals Announces Participation in the HIT-CF Project on Cystic Fibrosis GlobeNewswire
Feb-20-19 04:00PM  Eloxx Pharmaceuticals to Present at the Barclays Global Healthcare Conference on March 14, 2019 GlobeNewswire
Feb-19-19 07:00AM  Eloxx Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 GlobeNewswire
Feb-14-19 08:40AM  Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019 GlobeNewswire +5.48%
Feb-13-19 11:12AM  Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on March 8, 2019 GlobeNewswire
Feb-04-19 07:00AM  Eloxx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference in New York City on Monday, February 11, 2019 GlobeNewswire
Jan-03-19 01:08PM  Eloxx Pharmaceuticals to Participate in a Panel Discussion at the BIOTECH SHOWCASE in San Francisco on Wednesday, January 9, 2019 GlobeNewswire
Dec-20-18 02:54PM  Could The Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Ownership Structure Tell Us Something Useful? Simply Wall St. +8.96%
Dec-19-18 05:37AM  Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't American City Business Journals
Dec-17-18 08:39PM  Edited Transcript of ELOX earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-20-18 07:00AM  Eloxx Pharmaceuticals To Present at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 GlobeNewswire
Nov-19-18 07:00AM  Eloxx Pharmaceuticals To Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018 GlobeNewswire
Nov-08-18 07:00AM  Eloxx Pharmaceuticals Reports Third Quarter 2018 Financial and Operating Results and Provides Business Update GlobeNewswire +18.73%
Oct-18-18 11:49AM  Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC) GlobeNewswire
Oct-16-18 06:16PM  Eloxx Pharmaceuticals To Report Third Quarter 2018 Financial Results and Provide Business Update On November 8, 2018 GlobeNewswire
Sep-24-18 07:00AM  Eloxx Pharmaceuticals To Present at the 8th Orphan Drugs & Rare Diseases Congress, the Oppenheimer Fall Summit, and the 2018 Cantor Global Healthcare Conference GlobeNewswire
Aug-07-18 04:01PM  Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update GlobeNewswire
Jul-18-18 07:30AM  Eloxx Pharmaceuticals To Present at the 38th Annual Canaccord Genuity Growth Conference GlobeNewswire
Jul-17-18 07:30AM  Eloxx Pharmaceuticals To Report Second Quarter 2018 Financial Results On August 7, 2018 and Host Webcast and Conference Call GlobeNewswire
Jun-25-18 04:20PM  Eloxx Expands Leadership Team with Two Global Pharmaceutical Executives to Accelerate Growth GlobeNewswire
Jun-18-18 07:30AM  Eloxx Appoints Global Pharmaceutical Leader, Neil Belloff, Executive Vice President, General Counsel and Corporate Secretary GlobeNewswire -10.40%
Jun-11-18 07:30AM  Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update CNW Group +9.17%
Jun-08-18 11:00AM  Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 41st European Cystic Fibrosis Conference (ECFS) GlobeNewswire
May-10-18 04:01PM  Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update GlobeNewswire
May-01-18 01:27PM  Eloxx Pharmaceuticals To Report First Quarter 2018 Financial Results On May 10, 2018 and Host Webcast and Conference Call GlobeNewswire +8.07%
Apr-30-18 04:01PM  Eloxx Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters Option to Purchase Additional Shares GlobeNewswire +7.63%
Apr-27-18 12:41PM  Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis GlobeNewswire
Apr-25-18 06:22PM  Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock GlobeNewswire
Apr-24-18 04:01PM  Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-18-18 11:30AM  Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference GlobeNewswire
Mar-19-18 07:00AM  Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update GlobeNewswire
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel ribonucleic acid for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which has completed Phase 1 clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.